Pfizer expands generics portfolio with Aurobindo, Claris deals
NEW YORK A big pharmaceutical company has entered licensing agreements with two Indian generics companies, expanding its portfolio by 75 products.
Pfizer announced Wednesday that the agreements, with Aurobindo Pharma and Claris Lifesciences, would “significantly expand” the portfolio of medicines in its Established Products Business Unit, giving it products to market in North America, Europe, Australia, New Zealand and more than 70 emerging market countries.
“[Today’s] announcement demonstrates Pfizer’s commitment to improving the global public health landscape by making needed quality medicines – in a range of disease areas – accessible to underserved populations worldwide,” Pfizer chairman and CEO Jeff Kindler stated. “The off-patent marketplace worldwide too often suffers from quality and supply reliability issues.”
Under the terms of the agreements, Pfizer has acquired the rights to 55 pill drugs and five injected drugs from Aurobindo to sell in emerging markets, and 15 injected drugs from Claris to sell in developed markets.
Bartell Drugs sponsors ‘Stock the Pantry’ food drive
SEATTLE Bartell Drugs has announced its sponsorship of its “Stock the Pantry” food drive to benefit a local food bank.
The regional chain said it would accept donations of nonperishable food for the organization Northwest Harvest at its 55 stores in the Seattle area from June 1 to 14.
The drive is designed to benefit families that depend on free or reduced-price school lunches during the summer months, when they may struggle to provide those meals at home.
FDA tenatively approves Teva pink eye generic
ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to Teva Pharmaceutical Industries for its generic version of a drug for eye infections, FDA records showed.
The agency gave Teva the tentative approval for its moxifloxacin hydrochloride ophthalmic solution in the 0.5% strength. The solution is a generic version of Alcon’s Vigamox, which is used to treat bacterial conjunctivitis, commonly known as pink eye.
Alcon does not list the sales figures for Vigamox, though it reported sales of drugs to treat infections and inflammations of $882.5 million for 2008 in Securities and Exchange Commission filings.